Sandoz Company, a global player in generic pharmaceuticals has introduced in to Nigerian market Candesartan brand of products for management of cardiovascular disease particularly hypertension, left ventricular hypertrophy (LVH) and heart failure.
The introduction of the product by Sandoz, a Novartis company, is on the background of high prevalence of heart related diseases among categories of people.
At the unveiling of the product in Lagos recently, the Country Head, Sandoz, Adedeji Idowu reiterated the commitment of Novartis through Sandoz to ensure access to quality medicine for the greatest number of people.
Consultant Physician and Cardiologist, LUTH Lagos A.C. Mbakwem took time at the venue to provide background on prevalence of hypertension, LVH and HF amongst Nigerian patients while Consultant Physician and Cardiologist OOUTH Sagamu, O.B. Familoni assessed current management options and the position of the global guidelines best practices on the disease.
The place of Candesartan in management of HTN, LVH and HF was examined by Dike Ojjiji, Consultant Physician and Cardiologist UATH Abuja.
The chairman of the occasion D.A. Oke CMD of LASUTH reiterated the view of all the speakers on the need for physicians to embrace a holistic approach in the management of hypertension and its attendant consequence and comorbidities.
Various studies have indicated high prevalence of hypertension in Nigeria. A published report had quoted researchers estimating more than 20 million cases of hypertension in 2010, affecting one in three men and one in four women a figure which is on the rise.
It is said that the symptoms of hypertension are not always obvious; this according to experts makes it important for people to regularly conduct check-up.
Daniel Obi
